David M. Brown, MD

Associate Professor of Clinical Ophthalmology, Academic Institute
Associate Clinical Member, Research Institute
Houston Methodist
Weill Cornell Medical College


After completing his postdoctoral training, Dr. Brown joined the faculty at the Baylor College of Medicine as a Clinical Instructor in the Department of Ophthalmology. He received his faculty appointment at the Weill Medical College in 2006.

Description of Research

Dr. Brown’s research centers on clinical investigations to evaluate treatments for diabetic retinopathy, neovascular age-related macular degeneration, central retinal vein occlusion, and retinal detachment. Dr. Brown was a key investigator on the Anti-VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age-related Macular Degeneration (ANCHOR) Study and the Minimally classic/occult trial of the anti-VEGF antibody ranibizumab in the treatment of neovascular AMD (MARINA) Study which both demonstrated a statistically significant benefit of Lucentis (ranibizumab) over Visudyne (verteporfin photodynamic therapy [PDT]) in predominantly classic choroidal neovascularization (CNV). Dr. Brown is also a member of the Diabetic Retinopathy Clinical Research Network.

Areas Of Expertise

Diabetic retinopathy Neovascular age-related macular degeneration Central retinal vein occlusion Retinal detachment
Education & Training

MD, Baylor College of Medicine
Internship, Baylor College of Medicine
Residency, University of Iowa Hospitals and Clinics

Fan, W, Fleming, A, Hemert, JV, Wykoff, CC, Brown, DM, Robertson, G, Wang, K, Falavarjani, KG, Sadda, SR & Ip, M 2022, , Retina, vol. 42, no. 10, pp. 1883-1888. https://doi.org/10.1097/IAE.0000000000003549

MERLIN: Phase 3a, Multicenter, Randomized, Double-Masked Trial of Brolucizumab in Participants with Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid
MERLIN Investigators 2022, , Ophthalmology, vol. 129, no. 9, pp. 974-985. https://doi.org/10.1016/j.ophtha.2022.04.028

KESTREL and KITE: 52-Week Results From Two Phase III Pivotal Trials of Brolucizumab for Diabetic Macular Edema
Brown, DM, Emanuelli, A, Bandello, F, Barranco, JJE, Figueira, J, Souied, E, Wolf, S, Gupta, V, Ngah, NF, Liew, G, Tuli, R, Tadayoni, R, Dhoot, D, Wang, L, Bouillaud, E, Wang, Y, Kovacic, L, Guerard, N & Garweg, JG 2022, , American Journal of Ophthalmology, vol. 238, pp. 157-172. https://doi.org/10.1016/j.ajo.2022.01.004

The Association of Fluid Volatility With Subretinal Hyperreflective Material and Ellipsoid Zone Integrity in Neovascular AMD
Ehlers, JP, Patel, N, Kaiser, PK, Heier, JS, Brown, DM, Meng, X, Reese, J, Lunasco, L, Le, TK, Hu, M & Srivastava, SK 2022, , Investigative Ophthalmology and Visual Science, vol. 63, no. 6, 17. https://doi.org/10.1167/iovs.63.6.17

Brown, DM, Boyer, DS, Csaky, K, Vitti, R, Perlee, L, Chu, KW, Asmus, F, Leal, S, Zeitz, O, Cheng, Y, Schmelter, T & Heier, JS 2022, , Retina, vol. 42, no. 6, pp. 1111-1120. https://doi.org/10.1097/IAE.0000000000003441

Fan, W, Nittala, MG, Wykoff, CC, Brown, DM, Uji, A, van Hemert, J, Fleming, A, Robertson, G, Sadda, SR & Ip, M 2022, , Retina, vol. 42, no. 3, pp. 426-433. https://doi.org/10.1097/IAE.0000000000003358

Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials
YOSEMITE and RHINE Investigators 2022, , The Lancet, vol. 399, no. 10326, pp. 741-755. https://doi.org/10.1016/S0140-6736(22)00018-6

Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials
TENAYA and LUCERNE Investigators 2022, , The Lancet, vol. 399, no. 10326, pp. 729-740. https://doi.org/10.1016/S0140-6736(22)00010-1

Baseline retinal vascular bed area on ultra-wide field fluorescein angiography correlates with the anatomical outcome of diabetic macular oedema to ranibizumab therapy: two-year analysis of the DAVE Study
Fan, W, Uji, A, Wykoff, CC, Brown, DM, van Hemert, J, Falavarjani, KG, Wang, K, Sadda, SVR & Ip, M 2023, , Eye (Basingstoke), vol. 37, no. 4, pp. 678-683. https://doi.org/10.1038/s41433-021-01777-7

Longitudinal analysis of aqueous humour cytokine expression and OCT-based imaging biomarkers in retinal vein occlusions treated with anti-vascular endothelial growth factor therapy in the IMAGINE study
Arepalli, S, Wykoff, CC, Abraham, JR, Lunasco, L, Yu, H, Hu, M, Srivastava, SK, Reese, JL, Brown, DM & Ehlers, JP 2022, , Eye (Basingstoke). https://doi.org/10.1038/s41433-022-02265-2

Evaluation of Intravitreal Aflibercept for the Treatment of Severe Nonproliferative Diabetic Retinopathy: Results from the PANORAMA Randomized Clinical Trial
Brown, DM, Wykoff, CC, Boyer, D, Heier, JS, Clark, WL, Emanuelli, A, Higgins, PM, Singer, M, Weinreich, DM, Yancopoulos, GD, Berliner, AJ, Chu, K, Reed, K, Cheng, Y & Vitti, R 2021, , JAMA Ophthalmology, vol. 139, no. 9, pp. 946-955. https://doi.org/10.1001/jamaophthalmol.2021.2809

Long-term outcomes of treat-and-extend ranibizumab with and without navigated laser for diabetic macular oedema: TREX-DME 3-year results
Payne, JF, Wykoff, CC, Clark, WL, Bruce, BB, Boyer, DS & Brown, DM 2021, , British Journal of Ophthalmology, vol. 105, no. 2, pp. 253-257. https://doi.org/10.1136/bjophthalmol-2020-316176

Aqueous Cytokine Expression and Higher Order OCT Biomarkers: Assessment of the Anatomic-Biologic Bridge in the IMAGINE DME Study
Abraham, JR, Wykoff, CC, Arepalli, S, Lunasco, L, Yu, HJ, Hu, M, Reese, J, Srivastava, SK, Brown, DM & Ehlers, JP 2021, , American Journal of Ophthalmology, vol. 222, pp. 328-339. https://doi.org/10.1016/j.ajo.2020.08.047

Intravitreal aflibercept injection vs sham as prophylaxis against conversion to exudative age-related macular degeneration in high-risk eyes a randomized clinical trial
Heier, JS, Brown, DM, Shah, SP, Saroj, N, Dang, S, Waheed, NK, Wykoff, CC, Prenner, JL & Boyer, DS 2021, , JAMA Ophthalmology, vol. 139, no. 5, pp. 542-547. https://doi.org/10.1001/jamaophthalmol.2021.0221

Retinal vascular bed area on ultra-wide field fluorescein angiography indicates the severity of diabetic retinopathy
Fan, W, Uji, A, Nittala, M, Wykoff, CC, Brown, D, Fleming, A, Robertson, G, Van Hemert, J, Sadda, SV & Ip, MS 2022, , British Journal of Ophthalmology, vol. 106, no. 8, pp. 1126-1131. https://doi.org/10.1136/bjophthalmol-2020-317488

Longitudinal Assessment of Ellipsoid Zone Integrity, Subretinal Hyperreflective Material, and Subretinal Pigment Epithelium Disease in Neovascular Age-Related Macular Degeneration
Ehlers, JP, Zahid, R, Kaiser, PK, Heier, JS, Brown, DM, Meng, X, Reese, J, Le, TK, Lunasco, L, Hu, M & Srivastava, SK 2021, , Ophthalmology Retina, vol. 5, no. 12, pp. 1204-1213. https://doi.org/10.1016/j.oret.2021.02.012

Brown, DM 2021, , Ophthalmology, vol. 128, no. 10, pp. e70. https://doi.org/10.1016/j.ophtha.2021.03.039

Venous overload choroidopathy: A hypothetical framework for central serous chorioretinopathy and allied disorders
Spaide, RF, Gemmy Cheung, CM, Matsumoto, H, Kishi, S, Boon, CJF, van Dijk, EHC, Mauget-Faysse, M, Behar-Cohen, F, Hartnett, ME, Sivaprasad, S, Iida, T, Brown, DM, Chhablani, J & Maloca, PM 2022, , Progress in Retinal and Eye Research, vol. 86, 100973. https://doi.org/10.1016/j.preteyeres.2021.100973

Exploring the angiographic-biologic phenotype in the IMAGINE study: Quantitative UWFA and cytokine expression
Abraham, JR, Wykoff, CC, Arepalli, S, Lunasco, L, Yu, HJ, Martin, A, Mugnaini, C, Hu, M, Reese, J, Srivastava, SK, Brown, DM & Ehlers, JP 2022, , British Journal of Ophthalmology, vol. 106, no. 10, pp. 1444-1449. https://doi.org/10.1136/bjophthalmol-2020-318726

Expanded Clinical Spectrum of Pentosan Polysulfate Maculopathy: A Macula Society Collaborative Study
Macula Society Pentosan Polysulfate Maculopathy Study Group 2021, , Ophthalmology Retina. https://doi.org/10.1016/j.oret.2021.07.004